3 recruiting, 2 completed, 1 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Completed 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow CNS Tumor: new trials by email Literature Review of CNS Tumor trials Research Report on CNS Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). BCB-276 - Diffuse Intrinsic Pontine Glioma, DIPG | Phase 2 | Recruiting | BrainChild Bio, Inc | 75 | 2026-09-04 | 2026-10-28 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-05-13 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling avapritinib - Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1 / Phase 2 | Completed | Blueprint Medicines Corporation | 29 | 2022-02-24 | 2026-01-13 |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Infigratinib - Advanced Solid Tumor, CNS Tumor | Phase 1 / Phase 2 | Withdrawn | Helsinn Healthcare SA | 2021-10-01 | 2023-02-23 | |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Antineoplaston therapy (Atengenal + Astugenal) - CNS Tumor | Phase 2 | Terminated | Burzynski Research Institute | 3 | 1999-03-01 | 2017-07-26 |
Central Nervous System Neoplasms (7) · Glioma (3) · Brain Neoplasms (2) · Neoplasms (2) · Neurilemmoma (2) · Neurofibroma (2) · Diffuse Intrinsic Pontine Glioma (1) · Meningioma (1) · Multiple Sclerosis (1) · Neuroinflammatory Diseases (1) · Neuroma, Acoustic (1) · Recurrence (1)
Neoplasms by Site (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Neuroepithelial (4) · Brain Diseases (2) · Central Nervous System Diseases (2) · Nerve Sheath Neoplasms (2) · Neuroendocrine Tumors (2) · Neuroma (2)
Carboplatin (1) · Cyclophosphamide (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Mn-PyC3A (1) · Nivolumab (1) · Surgical Procedures, Operative (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1) · avapritinib (1) · entinostat (1) · entrectinib (1) · infigratinib (1) · pegfilgrastim (1)
Blueprint Medicines Corporation (1) · BrainChild Bio, Inc (1) · Burzynski Research Institute (1) · Helsinn Healthcare SA (1) · Reveal Pharmaceuticals Inc. (1) · St. Jude Children's Research Hospital (1) · University Hospital Heidelberg (1)
United States (6) · Germany (3) · Australia (2) · Austria (2) · Canada (2) · France (2) · Brazil (1) · Italy (1) · Jordan (1) · Netherlands (1) · Peru (1) · South Korea (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Cori Abikoff, MD (1) · Daniel Moreira, MD, MEd (1) · Olaf Witt (1) · Stanislaw R. Burzynski, MD, PhD (1)
2018 (1), R44CA261240 (1)